化疗序贯EGFR-TKIs治疗晚期非小细胞肺癌的疗效分析

Therapeutic effect of sequential chemotherapy with EGFR-TKIs in the treatment of advanced non-small cell lung cancer

目的探讨化疗序贯表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKI)治疗晚期非小细胞肺癌的疗效。方法选取2016年2月~2018年1月在我院诊治的晚期NSCLC患者172例,根据随机数字表法分为EGFR组与对照组各86例。对照组给予常规化疗方案治疗,EGFR组在对照组治疗的基础上给予EGFR-TKIs序贯靶向治疗,两组均治疗观察2个疗程。结果EGFR组的总有效率为88.4%,显著高于对照组的57.5%(P<0.05)。两组治疗期间的毒副反应主要为白细胞减少、血小板降低、消化道反应、肝肾损害等,多数为Ⅰ~Ⅱ级,均可耐受,对比差异无统计学意义(P>0.05)。结论化疗序贯EGFR-TKIs治疗晚期NSCLC能提高治疗效果,且不会增加毒副反应的发生。

Objective To investigate the efficacy of chemotherapy-derived epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in the treatment of advanced non-small cell lung cancer. Methods From February 2016 to January 2018,172 patients with advanced NSCLC who were treated in our hospital were enrolled,and all them were equally divided into the EGFR group and control group accorded to the random number table,86 cases in each group.The control group was received conventional chemotherapy regimen,and the EGFR group was received sequential targeted therapy with EGFR-TKIs on the basis of the control group.Both groups were treated for 2 courses. Results The total effective rate of the EGFR group was 88.4%,which was significantly higher than 57.5% of the control group (P < 0.05).The toxic side effects during the two treatment periods were mainly leukopenia,thrombocytop enia,digestive tract reaction,liver and kidney damage,etc,most of them were grade Ⅰ~Ⅱ and were tolerated,and there was no significant difference between the two groups (P > 0.05). Conclusion Chemotherapy sequential EGFR-TKIs can improve the therapeutic effect of advanced NSCLC without increasing the incidence of side effects.